155 related articles for article (PubMed ID: 38437857)
1. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
Coppens M; Pipe SW; Miesbach W; Astermark J; Recht M; van der Valk P; Ewenstein B; Pinachyan K; Galante N; Le Quellec S; Monahan PE; Leebeek FWG;
Lancet Haematol; 2024 Apr; 11(4):e265-e275. PubMed ID: 38437857
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
[TBL] [Abstract][Full Text] [Related]
4. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.
Klamroth R; Bonner A; Gomez K; Monahan PE; Szafranski K; Zhang X; Walsh S; Wang D; Yan S
Haemophilia; 2024 Jan; 30(1):75-86. PubMed ID: 37902714
[TBL] [Abstract][Full Text] [Related]
5. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
Sekayan T; Simmons DH; von Drygalski A
Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
[TBL] [Abstract][Full Text] [Related]
6. Etranacogene Dezaparvovec: First Approval.
Heo YA
Drugs; 2023 Mar; 83(4):347-352. PubMed ID: 36802324
[TBL] [Abstract][Full Text] [Related]
7. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
von Drygalski A; Gomez E; Giermasz A; Castaman G; Key NS; Lattimore SU; Leebeek FWG; Miesbach WA; Recht M; Gut R; Dolmetsch R; Monahan PE; Le Quellec S; Pipe SW
Blood Adv; 2023 Oct; 7(19):5671-5679. PubMed ID: 36490302
[TBL] [Abstract][Full Text] [Related]
8. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G; Coppens M; Pipe SW
Expert Rev Hematol; 2023; 16(12):919-932. PubMed ID: 37882214
[TBL] [Abstract][Full Text] [Related]
9. Etranacogene dezaparvovec for hemophilia B gene therapy.
Thornburg CD
Ther Adv Rare Dis; 2021; 2():26330040211058896. PubMed ID: 37181105
[TBL] [Abstract][Full Text] [Related]
10. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
Von Drygalski A; Giermasz A; Castaman G; Key NS; Lattimore S; Leebeek FWG; Miesbach W; Recht M; Long A; Gut R; Sawyer EK; Pipe SW
Blood Adv; 2019 Nov; 3(21):3241-3247. PubMed ID: 31698454
[TBL] [Abstract][Full Text] [Related]
11. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
Srivastava A; Rangarajan S; Kavakli K; Klamroth R; Kenet G; Khoo L; You CW; Xu W; Malan N; Frenzel L; Bagot CN; Stasyshyn O; Chang CY; Poloskey S; Qiu Z; Andersson S; Mei B; Pipe SW
Lancet Haematol; 2023 May; 10(5):e322-e332. PubMed ID: 37003278
[TBL] [Abstract][Full Text] [Related]
12. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
Wilson M; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Yan S
J Manag Care Spec Pharm; 2024 Apr; ():1-12. PubMed ID: 38625717
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy.
Itzler R; Buckner TW; Leebeek FWG; Miller J; Recht M; Drelich D; Monahan PE; Pipe SW
Haemophilia; 2024 May; 30(3):709-719. PubMed ID: 38462823
[TBL] [Abstract][Full Text] [Related]
15. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
Young G; Srivastava A; Kavakli K; Ross C; Sathar J; You CW; Tran H; Sun J; Wu R; Poloskey S; Qiu Z; Kichou S; Andersson S; Mei B; Rangarajan S
Lancet; 2023 Apr; 401(10386):1427-1437. PubMed ID: 37003287
[TBL] [Abstract][Full Text] [Related]
17. Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec.
Anguela XM; High KA
Blood Adv; 2024 Apr; 8(7):1796-1803. PubMed ID: 38592711
[TBL] [Abstract][Full Text] [Related]
18. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.
Xue F; Li H; Wu X; Liu W; Zhang F; Tang D; Chen Y; Wang W; Chi Y; Zheng J; Du Z; Jiang W; Zhong C; Wei J; Zhu P; Fu R; Liu X; Chen L; Pei X; Sun J; Cheng T; Yang R; Xiao X; Zhang L
Lancet Haematol; 2022 Jul; 9(7):e504-e513. PubMed ID: 35598604
[TBL] [Abstract][Full Text] [Related]
19. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
